PHARMAC have awarded Sole Supply for Terazosin 2 mg and 5 mg to Apotex.
The new listing takes effect from 1 December 2016. Reference pricing will apply from 1 February 2017 and Terazosin-Actavis Tab 2 mg 28 and 5 mg 28 will be delisted from 1 May 2017.
Click here to read the notification from Apotex.
Good news is that you may continue to purchase and dispense Terazosin-Actavis Tab 2 mg 28 and 5 mg 28 up until 30 April 2017 and not risk any losses.
From 3 October 2016 to 31 January 2017 the price ex-manufacturer was reduced as follows;
Terazosin-Arrow Tab 2 mg 28 from $0.45 to $0.37 giving you additional margin of $0.08c per unit , but no additional packaging costs or time cost in count and pour.
Terazosin-Arrow Tab 5 mg 28 from $0.68 to $0.58 giving you additional margin of $0.10c per unit, but no additional packaging costs or time cost in count and pour.
From 1 February 2017 the subsidy will reduce on both strengths, but your ex-manufacturer will be as stated above, continuing to give you additional margin of $0.05c per unit on 2 mg and $0.03c per unit on 5 mg.
You must keep in mind there is no additional packaging costs no time cost in count and pour.